Icrucumab

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameIcrucumab
Drug Alias NameLY-301221218-F-1IMC-18-F-1
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionVascular endothelial growth factor receptor 1 antagonistsAngiogenesis inhibitors
TargetsVascular endothelial growth factor receptor 1
Therapy Area/IndicationsSolid tumoursUrethral NeoplasmsUreteral Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesImclone SystemsEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsSolid tumoursUrethral NeoplasmsUreteral Neoplasms +[8] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG